HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of signaling activity involving the AKT–mTOR pathway leading to trastuzumab insensitivity. We sought to investigate the p...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lipton, Allan, Goodman, Laurie, Leitzel, Kim, Cook, Jennifer, Sperinde, Jeff, Haddad, Mojgan, Köstler, Wolfgang J., Huang, Weidong, Weidler, Jodi M., Ali, Suhail, Newton, Alicia, Fuchs, Eva-Marie, Paquet, Agnes, Singer, Christian F., Horvat, Reinhard, Jin, Xueguang, Banerjee, Joyee, Mukherjee, Ali, Tan, Yuping, Shi, Yining, Chenna, Ahmed, Larson, Jeff, Lie, Yolanda, Sherwood, Thomas, Petropoulos, Christos J., Williams, Stephen, Winslow, John, Parry, Gordon, Bates, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2013
Témata:
Preclinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3758835/
https://ncbi.nlm.nih.gov/pubmed/23959396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2665-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky